 (ABIO) Stock, Quote.Headers.trade-ideas

ARCA biopharma

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABIO

AFRM

APLD

BCDA

BSLK

FIVE

JBDI

MESO

NTNX

OKTA

PSTG

QNTM

SPRC

TCBP

TOVX

Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

dna-3539309

ARCA Biopharma shares are trading higher by 8.1% Monday morning. The company announced a special dividend of $1.59 per share.

Why ARCA Biopharma Shares Are Trading Higher Today

Estée Lauder

Earnings

Long Ideas

PANW

Estée Lauder, Palo Alto Networks And 3 Stocks To Watch Heading Into Monday

Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced the completion of its previously announced merger with ARCA biopharma, Inc. The combined company will operate under the name Oruka Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Global Market today, September 3, 2024, under the ticker symbol "ORKA". In addition, Oruka announced the appointment of Samarth Kulkarni, PhD, current Chairman and CEO of CRISPR Therapeutics, as Chairman of Oruka's Board of Directors.
Concurrent with the merger, Oruka completed a previously announced $275 million private placement with a syndicate of new and existing investors including Fairmount, Venrock Healthcare Capital Partners, RTW Investments, Access Biotechnology, Commodore Capital, Deep Track Capital, Perceptive Advisors, Blackstone Multi-Asset Investing, Avidity Partners, Great Point Partners LLC, Paradigm BioCapital, Braidwell LP and Redmile Group, along with multiple large investment management firms. Following the merger, private placement, and reverse stock split, there are approximately 46.3 million shares of the combined company's common stock and common stock equivalents outstanding, including shares of common stock underlying pre-funded warrants and Series B non-voting convertible preferred stock, and excluding employee and director equity.

Management

ORKA

Oruka Therapeutics Completes Merger with ARCA Biopharma, Begins Trading Under ORKA, Appoints CRISPR CEO as Chairman

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Shares of Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) rose sharply in today's pre-market trading following strong fourth-quarter earnings and <a href="https://www.benzinga.com/news/earnings/24/08/40613433/affirm-stock-rallies-after-strong-q4-earnings-upbeat-q1-guidance-what-to-know">upbeat first-quarter guidance.</a>
Affirm reported quarterly losses of 14 cents per share, which beat the analyst consensus estimate of losses of 51 cents per share. Quarterly revenue came in at $659 million, which beat the consensus estimate by 9.17%.
Affirm Holdings shares jumped 18% to $37.24 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>BioCardia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) gained 109.5% to $4.61 in pre-market trading after FDA cleared the company to market its Morph DNA Steerable Introducer product family.</li>
<li>Autozi Internet Technology (Global) Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) rose 101.5% to $5.28 in today's pre-market trading after dipping around 35% on Wednesday. Autozi Internet Technology (Global) reported the pricing of its initial public offering of 2,500,000 Class A ordinary shares at a public offering price of $4 per Class A ordinary share.</li>
<li>Theriva Biologics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NYSE">TOVX</a>) gained 24.3% to $4.35 in pre-market trading after the company announced it received a US patent application notice of allowance for treating C. Difficile disease and other antibiotic-induced GI tract adverse effects.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) gained 21.2% to $2.00 in pre-market trading. BranchOut Food shares jumped 14% on Wednesday after the company reported a year-over-year increase in its H1 revenue results.</li>
<li>Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) gained 16.5% to $61.00 in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY25 revenue guidance above estimates.</li>
<li>Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) gained 13% to $5.50 in pre-market trading after gaining more than 10% on Wednesday.</li>
<li>23andMe Holding Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) gained 11.5% to $0.35 in the pre-market trading session after declining 4% on Wednesday.</li>
<li>Mesoblast Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) gained 7.5% to $6.85 in pre-market trading as the company reported FY24 results.</li>
<li>Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) rose 7% to $84.50 in pre-market trading after the company reported better-than-expected quarterly revenue results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Big Lots, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIG#NYSE">BIG</a>) shares declined 30.5% to $0.6463 in pre-market trading after a report suggesting the company is considering a bankruptcy filing.</li>
<li>SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) shares fell 19.7% to $0.3405 in pre-market trading.</li>
<li>Pure Storage, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) fell 15.3% to $50.60 in pre-market trading after the company reported second-quarter financial results.</li>
<li>Bolt Projects Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) fell 14.3% to $1.74 in today's pre-market trading.</li>
<li>TC Biopharm (Holdings) Plc  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) fell 12.7% to $3.58 in pre-market trading. TC BioPharm announced closing of upsized $6.0 million public offering.</li>
<li>JBDI Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBDI#NASDAQ">JBDI</a>) shares fell 11.9% to $13.34 in pre-market trading after gaining 50% on Wednesday. JBDI Holdings announced closing of $11.25 million initial public offering.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares declined 11.8% to $3.89 in pre-market trading after posting a wider-than-expected quarterly loss.</li>
<li>ARCA biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) declined 11.5% to $1.67 in pre-market trading after falling 10% on Wednesday.</li>
<li>Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) shares dipped 8.6% to $18.49 in pre-market trading after the company reported worse-than-expected second-quarter adjusted EPS results and cut its FY25 adjusted EPS guidance below estimates.</li>
<li>Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) shares fell 8.1% to $88.74 in pre-market trading following second-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40600017/wall-streets-most-accurate-analysts-spotlight-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Materials Stocks Delivering High-Dividend Yields</a></li>
</ul>

ARCA biopharma&nbsp;updates&nbsp;the previously announced final amount of the special cash dividend (the &quot;Special Dividend&quot;), which will now equal&nbsp;$1.613&nbsp;per share of ARCA&#39;s common stock, payable on August 28, 2024, to ARCA&#39;s stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA&#39;s Board of Directors on August 16, 2024, in connection with the previously announced merger (the &quot;Merger&quot;) with Oruka Therapeutics, Inc. (&quot;Oruka&quot;), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the &quot;Merger Agreement&quot;). The exact amount of the Special Dividend was calculated in accordance with the Merger Agreement and based on ARCA&#39;s reasonable, good faith approximation of the amount by which ARCA&#39;s net cash, as determined prior to the closing of the Merger, will exceed&nbsp;$5,000,000.

Dividends

Reported Earlier, ARCA Biopharma Updates Special Dividend To $1.613/Share In Preparation For Oruka Therapeutics Merger

WIIM

ARCA Biopharma shares are trading lower after the company announced a 1-for-12 reverse stock split in connection with its proposed merger with Oruka Therapeutics.

ARCA biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. &nbsp;
The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of stockholders held on August 22, 2024 (the "Special Meeting"), to be effected in the Board's discretion of not less than 1-for-6 and not more than 1-for-12. The final reverse stock split ratio of 1-for-12 was approved by the Board on August 22, 2024.
 &nbsp;

Stock Split

ARCA biopharma Announces 1-For-12 Reverse Stock Split In Connection With The Proposed Merger With Oruka Therapeutics; To Begin Trading On A Post-reverse Stock Split Basis On The Nasdaq Global Market On September 3, 2024, And Under The New Symbol "ORKA"

ARCA Biopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) shares are trading higher by 12.5% to $3.32 Monday morning after the company, on Friday, announced a special dividend of <a href="https://www.benzinga.com/pressreleases/24/08/g40425199/arca-biopharma-declares-special-dividend-in-connection-with-the-proposed-merger-with-oruka-therape">$1.59 per share</a> in connection with the upcoming merger with Oruka Therapeutics.
The dividend will be paid to stockholders of record as of August 26, with payment scheduled for August 28.
The company says the exact dividend amount may vary depending on ARCA&#8217;s net cash exceeding $5 million before the merger closes. The dividend payment is contingent upon ARCA stockholders approving the merger at a meeting on August 22, with the merger expected to close on August 29.
Read Also: <a href="https://www.benzinga.com/markets/asia/24/08/40436803/asia-ex-japan-markets-rise-europe-opens-in-green-gold-hits-new-high-while-dollar-weakens-global-mark">Asia Ex-Japan Markets Rise, Europe Opens In Green, Gold Hits New High While Dollar Weakens &#8211; Global Markets Today While U.S. Slept</a>
<h2 class="wp-block-heading">Is ABIO A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/ABIO">ARCA biopharma</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. ARCA Biopharma does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/ABIO">ARCA biopharma</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ABIO has a 52-week high of $4.49 and a 52-week low of $1.56.

ARCA Biopharma shares are trading higher after the company announced a special dividend of $1.59 per share.

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) to report quarterly earnings at 27 cents per share on revenue of $3.83 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Estée Lauder shares gained 0.3% to $95.21 in after-hours trading.</li>
<li>Analysts are expecting ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) to post quarterly earnings at $1.01 per share on revenue of $1.80 billion. The company will release earnings before the markets open. ZIM Integrated Shipping shares fell 0.2% to $19.02 in after-hours trading.</li>
<li>ARCA Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) announced a special dividend of $1.59 per share. ARCA Biopharma shares climbed 10.5% to $3.26 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>After the closing bell, Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is projected to report quarterly earnings at $2.24 per share on revenue of $732.22 million. Fabrinet shares gained 1% to $233.40 in the after-hours trading session.</li>
<li>Analysts expect Palo Alto Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NYSE">PANW</a>) to post quarterly earnings at $1.41 per share on revenue of $2.16 billion after the closing bell. Palo Alto shares fell 0.1% to $333.76 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40420521/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">Jim Cramer Recommends Buying Clorox: &#8216;CEO Has Done Remarkable Job&#8217;</a></li>
</ul>
Photo courtesy: Wikimedia Commons

Special dividend estimated to be $1.59 per share &nbsp;
Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka

ARCA Biopharma Declares Special Dividend Of $1.59

ARCA biopharma EPS -$0.18 Per Share

The Dow Jones index closed higher by over 650 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">ARCA biopharma</h3>
<ul>
<li>The Trade: ARCA biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 220,083 shares at</a> an average price of $3.18. To acquire these shares, it cost around $699,165.</li>
<li>What's Happening: On April 25, ARCA biopharma posted a first-quarter loss of 14 cents per share.</li>
<li>What ARCA biopharma Does: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases.</li>
</ul>
<h3 class="wp-block-heading">Anixa Biosciences</h3>
<ul>
<li>The Trade: Anixa Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) Director Arnold M Baskies <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,000 shares at</a> an average price of $3.09. To acquire these shares, it cost around $15,450.</li>
<li>What's Happening: On July 23, Anixa Biosciences announced that its collaborator, Moffit Cancer Center, has received FDA approval for an individual patient Investigational New Drug Application (IND) to allow a second dose of its CAR-T therapy for a patient that may be demonstrating clinical activity to the initial treatment.</li>
<li>What Anixa Biosciences Does: Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology.</li>
</ul>
<h3 class="wp-block-heading">Lifeloc Technologies</h3>
<ul>
<li>The Trade: Lifeloc Technologies, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LCTC#OTC">LCTC</a>) CFO Vern D Kornelsen <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 45,620 shares</a> at an average price of $3.80. The insider spent around $173,356 to buy those shares. </li>
<li>What's Happening: On July 26, Lifeloc Technologies named Adam Kashenberg to its Board of Directors.</li>
<li>What Lifeloc Technologies Does: Lifeloc Technologies Inc is a developer, manufacturer, and marketer of portable hand-held and fixed station breathalyzers and related accessories, supplies and education.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis <a href="https://www.benzinga.com/quote/CYAN/analyst-ratings">acquired a total of 10,000 shares </a>at an average price of $0.62. The insider spent around $6,200 to buy those shares.</li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984459/top-3-risk-off-stocks-that-are-set-to-fly-in-july">Top 3 Risk Off Stocks That Are Set To Fly In July</a></li>
</ul>

Penny Stocks

Insider Trades

ANIX

CYAN

LCTC

Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed higher by more than 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">ARCA biopharma</h3>
<ul>
<li>The Trade: ARCA biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 408,777 shares at</a> an average price of $3.49. To acquire these shares, it cost around $1.4 million.</li>
<li>What's Happening: On April 25, ARCA biopharma posted a first-quarter loss of 14 cents per share.</li>
<li>What ARCA biopharma Does: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases.</li>
</ul>
<h3 class="wp-block-heading">Citizens</h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIA#NYSE">CIA</a>) President and CEO Jon Stenberg <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 4,580 shares at</a> an average price of $2.59. To acquire these shares, it cost around $11,862.</li>
<li>What's Happening: On July 1, Citizens President Jon Stenberg was appointed Chief Executive Officer.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
<h3 class="wp-block-heading">Willamette Valley Vineyards</h3>
<ul>
<li>The Trade: Willamette Valley Vineyards, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVVI#NASDAQ">WVVI</a>) CEO James W Bernau <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,978 shares</a> at an average price of $3.92. The insider spent around $11,682 to buy those shares. </li>
<li>What's Happening: On May 13, the company said sales revenue for the three months ended March 31, 2024 and 2023 was $8,803,080 and $8,308,940, respectively.</li>
<li>What Willamette Valley Vineyards Does: Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis a<a href="https://www.benzinga.com/quote/aei/analyst-ratings">cquired a total of 10,000 shares</a> at an average price of $0.42. The insider spent around $4,200 to buy those shares.</li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3 class="wp-block-heading">Douglas Elliman</h3>
<ul>
<li>The Trade: Douglas Elliman Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) Director Mark Zeitchick <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 40,000 shares</a> at an average price of $1.18. The insider spent $47,196 to buy those shares.</li>
<li>What's Happening: On July 2, Douglas Elliman announced that it secured a $50 million growth investment from Kennedy Lewis Investment Management.</li>
<li>What Douglas Elliman Does: Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39748049/how-to-earn-500-a-month-from-bank-of-america-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Bank of America Stock Ahead Of Q2 Earnings</a></li>
</ul>

DOUG

WVVI

Citizens And 4 Other Stocks Under $5 Insiders Are Buying

<h3>Gainers</h3>
<ul>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares rose 29.7% to $0.25 during Monday's pre-market session. The market value of their outstanding shares is at $16.0 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares rose 22.41% to $2.99. The company's market cap stands at $8.2 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock increased by 19.09% to $1.31. The company's market cap stands at $8.6 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares moved upwards by 15.3% to $0.47. The market value of their outstanding shares is at $33.2 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares moved upwards by 15.12% to $0.78. The company's market cap stands at $11.6 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) stock moved upwards by 14.07% to $1.54. The company's market cap stands at $48.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 36.3% to $0.36 during Monday's pre-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) shares fell 29.62% to $7.7. The market value of their outstanding shares is at $216.1 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 20.8% to $4.0. The company's market cap stands at $1.3 million. </li>
<li>ARCA biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) shares decreased by 14.03% to $2.82. The market value of their outstanding shares is at $40.9 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) stock declined by 13.45% to $3.22. The market value of their outstanding shares is at $5.8 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 13.24% to $0.81. The company's market cap stands at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCLI

CERO

CLDI

CNSP

CODX

ENTO

RNAZ

SBFM

SKYE

VERO

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock moved upwards by 70.4% to $3.51 during Monday's pre-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares moved upwards by 21.72% to $4.38. The company's market cap stands at $144.0 million. </li>
<li>Structure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) shares moved upwards by 19.23% to $40.78. The company's market cap stands at $1.9 billion. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock rose 16.78% to $1.6. The company's market cap stands at $16.2 million. </li>
<li>Kyverna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) shares increased by 16.6% to $14.61. The market value of their outstanding shares is at $629.9 million. </li>
<li>ARCA biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) stock rose 15.4% to $4.27. The market value of their outstanding shares is at $61.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Galera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) stock decreased by 36.5% to $0.14 during Monday's pre-market session. The market value of their outstanding shares is at $7.4 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock fell 20.99% to $0.38. The market value of their outstanding shares is at $7.4 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock declined by 17.4% to $0.36. The company's market cap stands at $3.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares declined by 15.5% to $1.5. The market value of their outstanding shares is at $9.9 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares declined by 13.29% to $0.24. The market value of their outstanding shares is at $45.2 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock declined by 8.51% to $0.19. The company's market cap stands at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

BPTH

GPCR

GRTX

ISPC

KYTX

MOLN

NIVF

PRTG

SNOA

<h3>Gainers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 103.8% to $0.27 during Friday's regular session. The company's market cap stands at $8.6 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) shares rose 48.66% to $0.18. The company's market cap stands at $6.7 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock increased by 29.77% to $8.63. The company's market cap stands at $8.9 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 27.23% to $1.13. The market value of their outstanding shares is at $6.8 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock increased by 26.73% to $0.18. The market value of their outstanding shares is at $3.9 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) stock increased by 17.98% to $28.01. The market value of their outstanding shares is at $5.2 billion. The company's, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) shares decreased by 21.1% to $1.25 during Friday's regular session. The company's market cap stands at $2.2 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares decreased by 15.36% to $0.12. The market value of their outstanding shares is at $14.5 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares declined by 15.01% to $1.87. The company's market cap stands at $1.6 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>ARCA biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) stock decreased by 14.75% to $3.41. The company's market cap stands at $49.4 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares fell 14.19% to $0.72. The company's market cap stands at $15.5 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares declined by 13.09% to $0.22. The company's market cap stands at $3.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

BBLG

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DOCS

KTTA

LSDI

ONCO

SINT

12 Health Care Stocks Moving In Friday's Intraday Session

Several stocks with high short interest rallied on Monday following an incredible surge in GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares. Here&#8217;s a quick look at <a href="https://www.benzinga.com/news/24/05/38789552/are-meme-stocks-back-heres-whats-going-on-with-shares-of-gamestop-amc-entertainment-koss-corp-and-mo">what you need to know</a>.
What To Know: The madness in meme stocks on Monday can be traced back to a social media post from Keith Gill, best known as "Roaring Kitty" on YouTube and X or "DeepF&#x2A;&#x2A;&#x2A;ingValue" on Reddit.
Following three years of silence, Gill took to X over the weekend, posting a <a href="https://twitter.com/TheRoaringKitty/status/1789807772542067105">meme</a> of a sketched person leaning forward in a chair. GameStop shares more than doubled in Monday&#8217;s session before pulling back. The stock still closed up nearly 75% for the day.
Several names with high short interest ripped higher in the wake of the GameStop rally. 
Yes, a simple meme kicked off a buying frenzy in heavily shorted names.
Some of the biggest movers included retail darlings AMC Entertainment Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>), Koss Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>), Tupperware Brands Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUP#NYSE">TUP</a>), VinFast Auto Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) and BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) — the usual suspects.
Other big movers on Monday included Beyond Meat Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>), Plug Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>), QuantumScape Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>), IRobot Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) and Newegg Commerce Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>), among others.
Check This Out: <a href="https://www.benzinga.com/general/gaming/24/05/38799011/gamestop-dives-into-collectibles-market-with-pok-mon-trading-cards">GameStop Dives Into Collectibles Market With Pokémon Trading Cards</a>
Why It Matters: The common thread between these names is that they are all heavily shorted. Retail traders tend to target heavily shorted names in an attempt to induce short squeezes that can spark massive moves higher when short sellers are forced to cover their positions. Check out <a href="http://pro.benzinga.com">Benzinga Pro</a> for more information on heavily shorted stocks.
What&#8217;s Next: If you want to try to get ahead of the next move, there are a couple of places to look, including <a href="https://www.benzinga.com/general/health-care/24/05/38763450/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Benzinga&#8217;s Stock Whisper Index</a>, which tracks stocks that investors secretly monitor, but are not talking about yet.
You can also use a screener to identify heavily shorted stocks or names with a high cost to borrow. According to Fintel <a href="https://fintel.io/shortSqueeze">data</a>, Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) currently has the highest likelihood of experiencing a short squeeze. It&#8217;s followed closely by ARCA Biopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>), Rent The Runway Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>), SilverSun Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNT#NASDAQ">SSNT</a>) and Mullen Automotive Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>).
When sorting the short squeeze leaderboard by short float, SunPower Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) jumps to the top of the list. Trump Media and ARCA Biopharma are the only names to appear again in the top five, listed second and third, respectively.
It&#8217;s worth noting that more than 177 million GameStop shares changed hands on Monday versus GameStop&#8217;s 100-day average of less than 7 million, per <a href="http://pro.benzinga.com">Benzinga Pro</a>. The stock is still trending across various social platforms at the time of publication.
Read Next: <a href="https://www.benzinga.com/general/education/24/05/38793704/who-is-roaring-kitty-why-does-his-return-to-social-media-matter-for-gamestop-stock">Who Is Roaring Kitty? Why Does His Return To Social Media Matter For GameStop Stock? </a>
Photo: <a href="https://pixabay.com/users/heungsoon-4523762/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5262730">HeungSoon</a> from Pixabay.

Short Sellers

Social Media

General

BYND

IRBT

KOSS

MULN

NEGG

PLUG

RENT

SPWR

SSNT

GameStop Trader 'Roaring Kitty' Sparks Wall Street Rally In Heavily Shorted Stocks: What You Need To Know Right Now

ARCA biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) reported quarterly losses of $(0.14) per share. This is a 55.56 percent decrease over losses of $(0.09) per share from the same period last year.

ARCA biopharma Q1 EPS $(0.14) Down From $(0.09) YoY

ARCA biopharma 13D Filing Shows Adage Capital Management, L.P. Reported A 8.28% Stake In The Co As Of April 3, 2024

Altice USA, Genfit, Brooge Energy among premarket losers' pack

ARCA Biopharma stock drops on CEO departure

The latest announcement is out from Arca Biopharma (ABIO). ARCA biopharma, Inc. has approved a significant 33.33% increase to the retention bonuses...

Arca Biopharma Increases Executive Retention Bonuses

ARCA biopharma GAAP EPS of -$0.14

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ARCA biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/abio-stock-quote/">ABIO</a>) just reported results for the first quarter of 2024.<ul><li>ARCA biopharma reported earnings per share of -14 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/abio-stock-earnings-arca-biopharma-for-q1-of-2024/">ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Yesterday, the forgotten <a href="https://investorplace.com/stock-types/meme-stocks/">meme stocks</a> of 2021 started picking up serious momentum. But unlike 2021, it didn&rsquo;t take much to see the reason behind GameStop&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/gme-stock-quote/">GME</a>) sudden surge. Keith Gill, the Massachusetts financial advisor credited with launching the GME short squeeze of 2021, unexpectedly returned to social media, <a href="https://twitter.com/TheRoaringKitty/status/1789807772542067105">posting</a> a single, cryptic image on his X account, where he goes by the alias Roaring Kitty. 



The image showed a hand-drawn man playing video games with no caption or further context. But the cult of r/WallStreetBets took it as a sign that their leader had returned and began hyping up their favorite short-squeeze stocks. This sparked a <a href="https://investorplace.com/2024/05/roaring-kitty-just-supercharged-gamestop-gme-stock/">massive rally</a> for GME and fellow unstable meme stock AMC Entertainment (NYSE:<a href="https://investorplace.com/stock-quotes/amc-stock-quote/">AMC</a>).



Even so, the Roaring Kitty rally appears to already be slowly losing steam. This should be expected when meme stocks unexpectedly surge. However, plenty of other companies with high short interest are also enjoying the ride, some of whom continue to rise steadily. SunPower Corporation (NASDAQ:<a href="https://investorplace.com/stock-quotes/spwr-stock-quote/">SPWR</a>) is up 84% today and remains on an upward trajectory. This means that the short-squeeze stocks to watch for maximum gains are likely lesser-known companies. A quick look at the <a href="https://fintel.io/shortSqueeze">short squeeze leaderboard </a>from Fintel reveals several key stocks to watch.



<h2>Short-Squeeze Stocks: Arca Biopharma (ABIO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/abio1600-300x169.png" alt="Illustrative Editorial of ARCA biopharma Inc website homepage. ARCA biopharma Inc logo visible on display screen. ABIO stock"><div>Source: Pavel Kapysh / Shutterstock.com</div></div>Arca Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/abio-stock-quote/">ABIO</a>) hasn&rsquo;t had a positive catalyst since early 2024 when Arca <a href="https://investorplace.com/2024/04/why-is-arca-biopharma-abio-stock-up-85-today/">announced plans</a> to merge with Oruka Therapeutics. But now this clinical-stage biopharmaceutical firm boasts some of the highest short interest of any current stock. ABIO hasn&rsquo;t benefited from the Roaring Kitty rally so far but investors should keep a close eye on it.



The stock boasts a Fintel short squeeze score of 98.79, with <a href="https://fintel.io/ss/us/abio">more than 83%</a> of its shares being sold short. The borrow fee rate ABIO shares is $83.72. ABIO&rsquo;s ranking on the short squeeze leaderboard has recently jumped 5 places. Granted, there are still 20,000 shares available to short. However, this little-known company is one of the most likely short-squeeze stocks to watch, and it currently trades at low levels. That could be tempting for speculative traders.



<h2>Rent the Runway (RENT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/shutterstock_2097733342-300x169.png" alt="RENT stock: Person holding cellphone with logo of US e-commerce company Rent the Runway Inc on screen in front of business webpage"><div>Source: Wirestock Creators / Shutterstock</div></div>A few months ago, many people had written this fashion retailer off. Now Rent the Runway (NASDAQ:<a href="https://investorplace.com/stock-quotes/rent-stock-quote/">RENT</a>) has watched its share prices more than double over the past month. Most of this growth isn&rsquo;t meme stock momentum. Unlike GME and AMC, RENT actually started rising after a <a href="https://investorplace.com/2024/04/why-is-rent-the-runway-rent-stock-up-30-today/">strong earnings report</a>, which is exactly the kind of catalyst that investors should look for. But now it ranks highly on Fintel&rsquo;s leaderboard of likely short-squeeze stocks.



While short interest accounts for only 19% of its float, as of this writing, there are no shares of RENT available to short and the cost to borrow shares is high, at $314. Overall, Rent the Runway boasts a short squeeze score of 97.73, one of the highest on the board.



<h2>Short-Squeeze Stocks: SilverSun Technologies (SSNT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/05/ssnt1600-300x169.png" alt="January 13, 2023, Brazil. In this photo illustration, the SilverSun Technologies logo is displayed on a smartphone screen. SSNT stock"><div>Source: rafapress / Shutterstock.com</div></div>This software company has been subject to significant volatility lately. SilverSun Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/ssnt-stock-quote/">SSNT</a>) is currently rising after taking multiple dips over the past month. It hasn&rsquo;t had too many catalysts to report, but over the past two quarters, shares have managed to remain mostly in the green. Through it all, though, short sellers don&rsquo;t seem to have much confidence in its growth prospects.



Short interest accounts for <a href="https://fintel.io/ss/us/ssnt">25% of its float</a>, and the cost to borrow shares is currently $16.49, with 40,000 shares available to short. This has led to SSNT receiving a short squeeze score of 96.61. This isn&rsquo;t as high as the previous short-squeeze stocks, but it is still significant, making it a prime short-squeeze candidate.



On the date of publication, Samuel O&rsquo;Brient&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



 
<div>Samuel O&rsquo;Brient is a Reporter for InvestorPlace, where his work focuses primarily on financial markets, global economic trends, and public policy. O&rsquo;Brient writes a weekly column on recent political news that investors should be following.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/3-short-squeeze-stocks-ready-to-soar-on-roaring-kitty-rally/">3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally

ARCA biopharma GAAP EPS of -$0.18

ARCA biopharma declares $1.59 dividend

ARCA biopharma approves 1-for-12 reverse stock split

ARCA biopharma declares $1.59 special dividend

ATUS

BROG

GNFT

ZCMD

Press Releases

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates PIK, CHX, MODN, ABIO

Kuehn Law Encourages ABIO, SQSP, SSB, and HMNF Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, HIBB, ABIO, HMNF

Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka

SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate ABIO, MODN, DPSI, AIRC

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Health Care

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

(ABIO) Forecast

(ABIO) Stock, Quote.Headers.trade-ideas